Institution
I.M. Sechenov First Moscow State Medical University
Education•Moscow, Russia•
About: I.M. Sechenov First Moscow State Medical University is a education organization based out in Moscow, Russia. It is known for research contribution in the topics: Medicine & Population. The organization has 7984 authors who have published 9355 publications receiving 68997 citations.
Topics: Medicine, Population, Cancer, Disease, Blood pressure
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The present review focuses on major physiological gastro-intestinal tract challenges involved in altering the pharmacokinetics of delivery systems, pathophysiology of MH and fibrosis, reported drug-polysaccharide cargos and focusing on conventional to advanced disease responsive delivery strategies, highlighting their limitations and future perspectives in intestinal inflammation therapy.
116 citations
••
TL;DR: Experimental preparations and methods for recording and studying Ca 2+ activity in astrocytes are described and their limitations and the ongoing technical and conceptual challenges in the interpretation ofAstrocytic Ca 2+.
Abstract: Astrocytes functionally interact with neurons and with other brain cells. Although not electrically excitable, astrocytes display a complex repertoire of intracellular Ca2+ signalling that evolves in space and time within single astrocytes and across astrocytic networks. Decoding the physiological meaning of these dynamic changes in astrocytic Ca2+ activity has remained a major challenge. This Review describes experimental preparations and methods for recording and studying Ca2+ activity in astrocytes, focusing on the analysis of Ca2+ signalling events in single astrocytes and in astrocytic networks. The limitations of existing experimental approaches and ongoing technical and conceptual challenges in the interpretation of astrocytic Ca2+ events and their spatio-temporal patterns are also discussed. Although not electrically excitable, astrocytes display a complex repertoire of intracellular Ca2+ signalling. Semyanov, Henneberger and Agarwal describe experimental preparations and methods for studying Ca2+ activity in astrocytes, their limitations and the ongoing technical and conceptual challenges in the interpretation of astrocytic Ca2+ events and their spatio-temporal patterns.
115 citations
••
TL;DR: Patients with chronic spontaneous urticaria are widely held to often have other autoimmune disorders, including autoimmune thyroid disease, and the literature on the prevalence of thyroid autoimmunity in CSU and vice versa is evaluated.
Abstract: Patients with chronic spontaneous urticaria (CSU) are widely held to often have other autoimmune disorders, including autoimmune thyroid disease. Here, we systematically evaluated the literature on the prevalence of thyroid autoimmunity in CSU and vice versa. There is a strong link between CSU and elevated levels of IgG antithyroid autoantibodies (AAbs), with most of a large number of studies reporting rates of ≥10%. Levels of IgG against thyroid peroxidase (TPO) are more often elevated in CSU than those of other IgG antithyroid AAbs (strong evidence). Levels of IgG antithyroid AAbs are more often elevated in adult patients with CSU than in children (strong evidence). Patients with CSU exhibit significantly higher levels of IgG antithyroid AAbs (strong evidence) and IgE-anti-TPO (weak evidence) than controls. Elevated IgG antithyroid AAbs in CSU are linked to the use of glucocorticoids (weak evidence) but not to disease duration or severity/activity, gender, age, or ASST response (inconsistent evidence). Thyroid dysfunction rates are increased in patients with CSU (strong evidence). Hypothyroidism and Hashimoto's thyroiditis are more common than hyperthyroidism and Graves' disease (strong evidence). Thyroid dysfunction is more common in adult patients with CSU than in children (strong evidence) and in female than in male patients with CSU (weak evidence). Urticaria including CSU is more prevalent in patients with thyroid autoimmunity than in controls (weak evidence). CSU can improve in response to treatment with levothyroxine or other thyroid drugs (strong evidence). Pathogenic mechanisms in CSU patients with thyroid autoimmunity may include IgE against autoantigens, immune complexes, and complement.
115 citations
••
Radboud University Nijmegen1, Medical University of Vienna2, Harvard University3, University of Amsterdam4, Charité5, University of Manchester6, University Hospitals Birmingham NHS Foundation Trust7, University of Birmingham8, University of Aberdeen9, Autonomous University of Barcelona10, Queen Mary University of London11, University of Barcelona12, I.M. Sechenov First Moscow State Medical University13, Erasmus University Rotterdam14, Paris Descartes University15, Huntsman Cancer Institute16, National and Kapodistrian University of Athens17, University of British Columbia18, Memorial Sloan Kettering Cancer Center19, University of Grenoble20, Erasmus University Medical Center21, Institut Gustave Roussy22, Università telematica San Raffaele23, University of Regensburg24, Humanitas University25, University of Paris26, University of Southampton27, University Hospital of Lausanne28, Utrecht University29, Ghent University Hospital30, Aberdeen Royal Infirmary31, University of Bologna32, Monash University, Clayton campus33, The Royal Marsden NHS Foundation Trust34, University of California, San Diego35, University of Erlangen-Nuremberg36, University of Western Australia37, University of Leeds38, University of Milan39, University of Glasgow40, University of Texas MD Anderson Cancer Center41, University of Oxford42, University Medical Center Groningen43, Copenhagen University Hospital44, University of Zurich45, Université Paris-Saclay46, Royal Surrey County Hospital47, University of Tübingen48, Akershus University Hospital49, Leiden University Medical Center50, University of Minho51, University of Sydney52, Technische Universität München53, Brighton and Sussex Medical School54, University of Hamburg55, Ruhr University Bochum56, Cornell University57, University of Lyon58, Monash University59, Umeå University60, University of Bern61, Cliniques Universitaires Saint-Luc62, Katholieke Universiteit Leuven63, University of Medicine, Pharmacy, Science and Technology of Târgu Mureș64, Metropolitan University65, Mount Sinai Health System66, Auckland City Hospital67, University of Graz68, Institute of Cancer Research69
TL;DR: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey as mentioned in this paper, and 22 of 27 (81%) statements achieved consensus.
114 citations
••
TL;DR: In this article, the authors evaluated the efficacy of canakinumab, an anti-interleukin-1β antibody, in patients hospitalized with severe COVID-19.
Abstract: Importance Effective treatments for patients with severe COVID-19 are needed. Objective To evaluate the efficacy of canakinumab, an anti–interleukin-1β antibody, in patients hospitalized with severe COVID-19. Design, Setting, and Participants This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States. A total of 454 hospitalized patients with COVID-19 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin were enrolled between April 30 and August 17, 2020, with the last assessment of the primary end point on September 22, 2020. Intervention Patients were randomly assigned 1:1 to receive a single intravenous infusion of canakinumab (450 mg for body weight of 40- 80 kg; n = 227) or placebo (n = 227). Main Outcomes and Measures The primary outcome was survival without IMV from day 3 to day 29. Secondary outcomes were COVID-19–related mortality, measurements of biomarkers of systemic hyperinflammation, and safety evaluations. Results Among 454 patients who were randomized (median age, 59 years; 187 women [41.2%]), 417 (91.9%) completed day 29 of the trial. Between days 3 and 29, 198 of 223 patients (88.8%) survived without requiring IMV in the canakinumab group and 191 of 223 (85.7%) in the placebo group, with a rate difference of 3.1% (95% CI, −3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76 to 2.54;P = .29). COVID-19–related mortality occurred in 11 of 223 patients (4.9%) in the canakinumab group vs 16 of 222 (7.2%) in the placebo group, with a rate difference of −2.3% (95% CI, −6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30 to 1.50). Serious adverse events were observed in 36 of 225 patients (16%) treated with canakinumab vs 46 of 223 (20.6%) who received placebo. Conclusions and Relevance Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV at day 29. Trial Registration ClinicalTrials.gov Identifier:NCT04362813
113 citations
Authors
Showing all 8045 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yehuda Shoenfeld | 125 | 1629 | 77195 |
Jatin P. Shah | 119 | 725 | 45680 |
Shahrokh F. Shariat | 118 | 1637 | 58900 |
Vladimir P. Torchilin | 109 | 627 | 58977 |
Klaus-Peter Lesch | 106 | 524 | 50099 |
Jürgen Kurths | 105 | 1038 | 62179 |
Rudolf Valenta | 102 | 748 | 38349 |
Valerian E. Kagan | 97 | 667 | 39888 |
Hans-Uwe Simon | 96 | 461 | 51698 |
Gleb B. Sukhorukov | 96 | 440 | 35549 |
Michael Aschner | 91 | 806 | 32826 |
Alexei Verkhratsky | 89 | 450 | 29788 |
Claudio L. Bassetti | 88 | 524 | 25332 |
Helgi B. Schiöth | 85 | 531 | 28628 |
Angelo Ravelli | 79 | 415 | 23439 |